BB Biotech Delivers Strong 2025 Results and Raises Dividend Proposal

BB Biotech ( (CH:BION) ) just unveiled an update.

BB Biotech AG reported strong results for 2025, publishing its annual report that includes audited consolidated financial statements and detailed commentary on the biotechnology sector, its investment themes and portfolio positions. As a specialized biotech investor, the company continues to position itself as a key vehicle for exposure to innovative drug developers in the U.S. and Western Europe.

For the 2025 financial year, BB Biotech’s share delivered a total return of 34.2% in CHF, 37.0% in EUR and 53.7% in USD, including the March 2025 dividend of CHF 1.80. Net profit surged to CHF 578 million from CHF 76 million a year earlier, while NAV performance reached 26.5% in CHF, 27.8% in EUR and 44.8% in USD, underscoring a marked improvement in portfolio performance.

The board will propose a dividend of CHF 2.25 per share at the upcoming Annual General Meeting, corresponding to a 5% yield on the volume‑weighted average share price in December 2025. This maintains BB Biotech’s established distribution policy, signaling continuity and income visibility for shareholders alongside the strong capital gains generated in 2025.

The most recent analyst rating on (CH:BION) stock is a Hold with a CHF54.00 price target. To see the full list of analyst forecasts on BB Biotech stock, see the CH:BION Stock Forecast page.

More about BB Biotech

BB Biotech AG is a Swiss investment company based in Schaffhausen and listed on the Swiss, German and Italian stock exchanges. Since 1993, it has focused on investing in innovative drug development companies, primarily in the U.S. and Western Europe, with strategy set by its experienced board and portfolio decisions executed by Bellevue Asset Management’s investment team.

Positioned as one of the leading investors in the biotechnology sector, BB Biotech leverages comprehensive investment research to build and manage a concentrated portfolio. Its market focus is on high-potential biotech firms developing novel therapies, aiming to capture value from medical innovation and long‑term industry growth.

The company targets investors seeking dedicated exposure to biotechnology through an actively managed, listed vehicle. Its long-standing presence and sector specialization have made it a reference name for biotech investment in continental Europe.

Average Trading Volume: 82,415

Technical Sentiment Signal: Buy

Current Market Cap: CHF2.53B

For a thorough assessment of BION stock, go to TipRanks’ Stock Analysis page.